An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment
Francis J., Barnes KI., Workman L., Kredo T., Vestergaard LS., Hoglund RM., Byakika-Kibwika P., Lamorde M., Walimbwa SI., Chijioke-Nwauche I., Sutherland CJ., Merry C., Scarsi KK., Nyagonde N., Lemnge MM., Khoo SH., Bygbjerg IC., Parikh S., Aweeka FT., Tarning J., Denti P.
Treating malaria in HIV-coinfected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers).